skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.10e (Release date: 2017-10-30)
SearchBox Top
SearchBox Bottom
VEGFR1-1084 Peptide Vaccine (Code C77895)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: VEGFR1-1084 Peptide Vaccine

Definition: A peptide vaccine containing an HLA-A*2402-restricted epitope of vascular endothelial growth factor receptor 1 (VEGFR1 or Flt-1) with potential immunostimulating, antiangiogenic, and antineoplastic activities. Upon vaccination, VEGFR1-1084 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against VEGFR1-expressing endothelial cells of the tumor microvasculature, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR1, a receptor tyrosine kinase, may be overexpressed on endothelial cells of the tumor microvasculature and is associated with tumor cell proliferation, invasion and tumor angiogenesis. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenicity.

Label: VEGFR1-1084 Peptide Vaccine

NCI Thesaurus Code: C77895 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL383575  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
VEGFR1-1084 Peptide Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 594364
PDQ Open Trial Search ID 594364 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C77895
Legacy_Concept_Name VEGFR1-1084_Peptide_Vaccine
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom